SMARCA4 and central nervous system cancer: Patients >6 months-<40 years of age with relapsed or refractory malignant rhabdoid tumor, rhabdoid tumor of the kidney, epitheloid sarcoma, chordoma, other INI1-negative or SMARCA4-deficient malignant tumors, atypical teratoid rhabdoid tumor (ATRT), other INI1-negative or SMARCA4-deficient primary CNS malignant tumors